Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a Phase 1b/2, multi-site, single-arm, open-label, non-randomized study looking at whether adding tocilizumab to standard treatment for metastatic Non-Small Cell Lung Cancer (NSCLC) is safe, possible, and effective. The study includes people with metastatic NSCLC, that is lung cancer that has spread, who have experienced significant loss of weight or muscle mass.
Epistemonikos ID: 3182cb6d470691783cdbc4b7342cc6f09544b6d5
First added on: Oct 23, 2026